NCT07436429 Drug-Coated Balloon Primary PCI in ST-Segment Elevation Myocardial Infarction
| NCT ID | NCT07436429 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of Vienna |
| Condition | Myocardial Infarction (MI) |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2026-02-08 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2026-02-08 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Drug-eluting stent (DES)-based primary percutaneous intervention (pPCI) has been established as the standard of care for patients presenting with ST-segment elevation myocardial infarction (STEMI), having demonstrated superiority over thrombolysis, plain balloon angioplasty, and bare-metal stents. Recently, the use of drug-coated balloons (DCB) has expanded dramatically across a variety of anatomical and clinical settings, including de novo coronary lesions. A DCB-based pPCI strategy may simplify the procedure and mitigate the risks of inadequate stent sizing due to spasm or large thrombus burden, acute stent thrombosis, distal embolization, no reflow, and the relatively higher incidence of late stent-related adverse events compared with elective PCI. Despite these theoretical advantages, data on the safety and efficacy of DCB-based pPCI in STEMI remains limited. The aim of this registry is to explore procedural and clinical outcomes of patients with STEMI treated with a DCB-based pPCI strategy.
Eligibility Criteria
Inclusion Criteria: * All ST-elevation MI undergoing Primary PCI Exclusion Criteria: * In-stent culprit lesion * Contraindications to antiplatelets * Stent implantation within 3 months before enrollment * Cardiac arrest, intubation, or cardiogenic shock * Life-expectancy less than one year
Contact & Investigator
Rayyan Hemetsberger, MD
PRINCIPAL INVESTIGATOR
Universitatsklinikum AKH wien
Frequently Asked Questions
Who can join the NCT07436429 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myocardial Infarction (MI). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07436429 currently recruiting?
Yes, NCT07436429 is actively recruiting participants. Contact the research team at riccardo.terzi1@gmail.com for enrollment information.
Where is the NCT07436429 trial being conducted?
This trial is being conducted at Vienna, Austria.
Who is sponsoring the NCT07436429 clinical trial?
NCT07436429 is sponsored by Medical University of Vienna. The principal investigator is Rayyan Hemetsberger, MD at Universitatsklinikum AKH wien. The trial plans to enroll 300 participants.